Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
976 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 976 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | Phase 2 | terminated | May 25, 2012 | Mayo Clinic | pending expiration of the supply of study agent. | Drug supply |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | Phase 1 | withdrawn | Apr 8, 2014 | The University of Texas Medical Branch, Galveston | Study did not get funded. Study never started | Funding |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients…(HCC DC CTL) | Phase 1 / Phase 2 | suspended | Jan 3, 2014 | HRYZ Biotech Co. | Interim analysis | Efficacy / futility |
| NCT00003522 | Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the…(ETAFIRM) | N/A | terminated | Oct 23, 2015 | Hospices Civils de Lyon | problems with enrollment | Enrollment / accrual |
| NCT01489410 | Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | N/A | withdrawn | Dec 9, 2011 | University of Minnesota | Insufficient staff | Other (stated, no rule matched) |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | Phase 3 | terminated | Dec 4, 2012 | Asan Medical Center | slow recruitment | Enrollment / accrual |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein… | Phase 1 | terminated | Aug 17, 2012 | Merck KGaA, Darmstadt, Germany | The sponsor decided not to conduct the expansion part of trial (part 2) | Sponsor / business decision |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | Phase 2 | terminated | Jul 1, 2016 | Chinese University of Hong Kong | Poor case accrual | Enrollment / accrual |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar… | — | withdrawn | Aug 30, 2010 | Bayer | Study is officially cancelled bevore FPFV. | Other (stated, no rule matched) |
| NCT02959359 | DAA in the Risk of Recurrence After Curative Treatment of HCC | Phase 4 | withdrawn | Nov 9, 2016 | Taipei Veterans General Hospital, Taiwan | The supplies of study drug were halted by Gilead Sciences Ltd. | Other (stated, no rule matched) |
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | — | terminated | May 3, 2010 | Stanford University | not stated | Not stated |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT01095523 | Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS… | Phase 2 | withdrawn | Mar 30, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Nov 10, 2008 | University of Washington | not stated | Not stated |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With… | Phase 1 | withdrawn | Aug 5, 2016 | Mayo Clinic | Site dropped study | Other (stated, no rule matched) |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile… | N/A | terminated | Feb 24, 2011 | Weill Medical College of Cornell University | EndoHPB probe is FDA approved and considered standard of care | Other (stated, no rule matched) |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | N/A | terminated | Nov 2, 2009 | University of Alabama at Birmingham | Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is… | Enrollment / accrual |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With…(BOS3) | Phase 2 / Phase 3 | withdrawn | Jul 20, 2012 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric…(MEGAN) | Phase 2 | withdrawn | Aug 5, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar…(PET/MRCP) | — | withdrawn | Jan 30, 2008 | University of Toronto | not stated | Not stated |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients…(PRIMIER) | Phase 2 | withdrawn | Apr 10, 2015 | University of Southern California | Study drug supply issues | Drug supply |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in…(SLAMF3) | — | withdrawn | Apr 13, 2017 | Centre Hospitalier Universitaire, Amiens | The study has been stopped because no one is | Other (stated, no rule matched) |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients… | Phase 2 | withdrawn | Jan 5, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma… | Phase 1 | terminated | Mar 18, 2015 | Millennium Pharmaceuticals, Inc. | The study was terminated because preliminary PK and overall clinical data demonstrated compelling… | Other (stated, no rule matched) |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | Phase 3 | terminated | Jul 29, 2011 | National Cancer Institute, Naples | lack of enrolment | Enrollment / accrual |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With… | Phase 1 / Phase 2 | terminated | May 22, 2009 | Cornerstone Pharmaceuticals | Suspended trial was not restarted. | Other (stated, no rule matched) |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Phase 1 | terminated | Dec 24, 2014 | Celgene | Slow enrollment and business decision. No safety concerns were identified for the study drugs. | Safety / toxicity |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage… | Phase 1 / Phase 2 | terminated | Aug 8, 2006 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | Phase 2 | terminated | Dec 18, 2007 | University of Pittsburgh | Bayer Healthcare is no supplying the study drug | Other (stated, no rule matched) |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | — | terminated | Jul 15, 2010 | Stanford University | accrual | Enrollment / accrual |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | Phase 2 | withdrawn | Jan 27, 2014 | Weill Medical College of Cornell University | Investigator terminated due to funding issues | Investigator |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | Phase 3 | terminated | Dec 18, 2014 | Assistance Publique - Hôpitaux de Paris | Decision of investigator | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 27, 2017source: clinicaltrials